Although EZH2 mutation alone may be insufficient to induce development of B-cell lymphoma, new evidence suggests it functions as a master regulator of GCB phenotype through repression of CDKN1A, IRF4, and PRDM1 (Beguelin et al., 2013). This evidence concerns the gene EZH2 and B-cell non-Hodgkin lymphoma.